Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Adverse drug events

European Medicines Agency launches safety review of HPV vaccines

A safety review of human papillomavirus (HPV) (pictured) vaccines, which protect young women against cervical cancer and other conditions, has been launched by the European Medicines Agency (EMA)

Source: Phanie / Alamy

The European Medicines Agency will look at rare reports of complex regional pain syndrome and postural orthostatic tachycardia syndrome among women vaccinated against the human papillomavirus

A safety review of human papillomavirus (HPV) vaccines, which protect young women against cervical cancer and other conditions, has been launched by the European Medicines Agency (EMA).

The review will look at rare reports of complex regional pain syndrome (CRPS) or postural orthostatic tachycardia syndrome (POTS) associated with the vaccines to try to determine whether there is a causal link. The review is not being conducted to question whether the benefits of the vaccines outweigh their risks.

Both conditions can occur in non-vaccinated individuals and the EMA wants to discover whether the number of reports of CRPS and POTS among women who receive the vaccines matches the number that would be expected among the general population.

HPV vaccination was introduced into the UK’s national childhood vaccination programme in 2008. It is offered to all 12–13 year olds in England, Wales and Northern Ireland and to all 11–13 year olds in Scotland.

HPV vaccines licensed in Europe include Cervarix, Gardasil and Gardasil 9. Gardasil is approved for use in males and females for preventing precancerous growths and cancer in the cervix and anus, and genital warts. It protects against four types of HPV (6, 11, 16 and 18); Gardasil 9 offers protection against nine virus types (6, 11, 16, 18, 31, 33, 45, 52 and 58); Cervarix is used in women and girls to protect against precancerous growths and cancer in the cervix and genital area and targets HPV types 16 and 18.

Based on its review, the EMA’s pharmacovigilance risk assessment committee will decide whether to recommend any changes to the vaccines’ product information. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068967

Readers' comments (1)

  • Well I think it is about time this vaccine was looked at under a microscope. As the mother of a child injured by this vaccine, the last 7 years have been virtually a medical nightmare for our family. My daughter has somewhat recovered but her growth was stunted at a vital maturation time in life. She received the three Gardasil injections in 2007 and 2008. She was 15 when she experienced the horrific side effects of the vaccine. An otherwise completely healthy young lady was knocked to the ground. She could not attend school which further damaged her future. She is rebounding today but is playing catch up on the maturation process. She will never reach the height she was meant to reach. She still suffers from anxiety disorder. I could go on and on with the list of symptoms I watched her suffer. I have also been in contact with a multitude of young ladies who have and are suffering from the same affliction. I sure hope an influential force can truly and un-neglectfully investigate how this abomination in the name of profit is destroying our youth and ultimately the global well-being of Earth's inhabitants, and put an end to it.

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • International Research in Healthcare

    International Research in Healthcare

    Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.

    £38.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.